Refeyn, a leading life science instrumentation company pioneering mass photometry, announced today that Dr. Susan Altschuller has been appointed a Non-Executive Director of Refeyn, effective October 1st, 2025.
Chief Financial Officer of Climb Bio, Inc.
Dr. Susan Altschuller is a seasoned biotechnology executive with over two decades of experience in the life sciences. She currently serves as Chief Financial Officer of Climb Bio, Inc.
Previously, Dr. Altschuller was CFO of Cerevel Therapeutics until its acquisition by AbbVie in 2024, and CFO of ImmunoGen, where she supported the commercial launch of an antibody-drug conjugate for ovarian cancer. She also held senior leadership roles at Alexion, Biogen, and Bioverativ, after beginning her career as a consultant with the Frankel Group.
Dr. Altschuller holds a BSE in Biomedical Engineering with Honors from Tulane University, a Ph.D. in Biomedical Engineering from the Illinois Institute of Technology, and an MBA from the MIT Sloan School of Management. She serves as Audit Chair on the Boards of Vestaron and Refeyn, and is a founding Board member of the HNRNP Family Foundation.
“We are pleased to welcome Susan to Refeyn’s Board,” said Jean-Paul Mangeolle, Refeyn’s Chairman. “Her financial expertise and deep understanding of both emerging biotech and global pharmaceutical companies will provide valuable insight as we scale and grow our presence in the life sciences tools market.”
To learn more about Refeyn’s Board of Directors, visit: About Us – Refeyn
